INTRODUCTION AND OBJECTIVES: The extent to which a patient's socioeconomic conditions determine the persistence or control of chronic Chagas disease has not been previously investigated. The aim of this study was to evaluate the effect of socioeconomic conditions on clinical and serologic measures of disease progression. METHODS: Data on the following socioeconomic variables were obtained by questioning as part of medical history taking at admission: birth in a rural area, time of residence in endemic and urban areas (in years), overcrowding index (i.e. number of inhabitants/number of bedrooms), absence of toilet facilities, years of education, employed or unemployed, and health insurance coverage (i.e. private contributory medical insurance cover). The study endpoints for the Cox regression analysis were: consistently negative results on serologic tests and on tests for markers of cardiomyopathy progression by the end of the study. RESULTS: The study included 801 Argentine patients (mean age 42 years) who were followed up for a mean of 10 years between 1990 and 2005. After adjustment for age and antiparasitic treatment, negative seroconversion was associated with a short time of residence in an endemic area (hazard ratio [HR]=0.97; 95% confidence interval [CI], 0.96-0.99; P=.004), a low overcrowding index (HR=0.82; 95% CI, 0.70-0.97; P=.022) and medical insurance cover (HR=1.46; 95% CI, 1.01-2.09; P=.04). After adjustment for age, sex, ECG abnormalities and antiparasitic treatment, a low rate of cardiomyopathy progression was associated with more years of education (HR=0.88; 95% CI, 0.80-0.97; P=.01) and higher medical insurance cover (HR=0.49; 95% CI, 0.30-0.81; P=.005). CONCLUSIONS: Socioeconomic conditions had a significant effect on chronic Chagas disease progression which was independent of antiparasitic treatment and clinic characteristics.
INTRODUCTION AND OBJECTIVES: The extent to which a patient's socioeconomic conditions determine the persistence or control of chronic Chagas disease has not been previously investigated. The aim of this study was to evaluate the effect of socioeconomic conditions on clinical and serologic measures of disease progression. METHODS: Data on the following socioeconomic variables were obtained by questioning as part of medical history taking at admission: birth in a rural area, time of residence in endemic and urban areas (in years), overcrowding index (i.e. number of inhabitants/number of bedrooms), absence of toilet facilities, years of education, employed or unemployed, and health insurance coverage (i.e. private contributory medical insurance cover). The study endpoints for the Cox regression analysis were: consistently negative results on serologic tests and on tests for markers of cardiomyopathy progression by the end of the study. RESULTS: The study included 801 Argentinepatients (mean age 42 years) who were followed up for a mean of 10 years between 1990 and 2005. After adjustment for age and antiparasitic treatment, negative seroconversion was associated with a short time of residence in an endemic area (hazard ratio [HR]=0.97; 95% confidence interval [CI], 0.96-0.99; P=.004), a low overcrowding index (HR=0.82; 95% CI, 0.70-0.97; P=.022) and medical insurance cover (HR=1.46; 95% CI, 1.01-2.09; P=.04). After adjustment for age, sex, ECG abnormalities and antiparasitic treatment, a low rate of cardiomyopathy progression was associated with more years of education (HR=0.88; 95% CI, 0.80-0.97; P=.01) and higher medical insurance cover (HR=0.49; 95% CI, 0.30-0.81; P=.005). CONCLUSIONS: Socioeconomic conditions had a significant effect on chronic Chagas disease progression which was independent of antiparasitic treatment and clinic characteristics.
Authors: Zulma M Cucunubá; Astrid C Flórez; Angela Cárdenas; Paula Pavía; Marleny Montilla; Rodrigo Aldana; Katherine Villamizar; Lyda C Ríos; Rubén S Nicholls; Concepción J Puerta Journal: Am J Trop Med Hyg Date: 2012-10-01 Impact factor: 2.345
Authors: R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191
Authors: Thirssa H Grando; Matheus D Baldissera; Mariângela F de Sá; Guilherme M do Carmo; Bianca Carolina Z Porto; Gisele S V Aguirre; Maria Isabel Azevedo; Francielli P K de Jesus; Janio M Santurio; Michele R Sagrillo; Lenita Moura Stefani; Silvia Gonzalez Monteiro Journal: J Immunol Methods Date: 2017-07-08 Impact factor: 2.303
Authors: María C Albareda; Ana M De Rissio; Gonzalo Tomas; Alicia Serjan; María G Alvarez; Rodolfo Viotti; Laura E Fichera; Mónica I Esteva; Daniel Potente; Alejandro Armenti; Rick L Tarleton; Susana A Laucella Journal: PLoS Negl Trop Dis Date: 2013-12-12
Authors: Colin J Forsyth; Salvador Hernandez; Carmen A Flores; Mario F Roman; J Maribel Nieto; Grecia Marquez; Juan Sequeira; Harry Sequeira; Sheba K Meymandi Journal: Am J Trop Med Hyg Date: 2018-01-25 Impact factor: 2.345
Authors: Claudia Di Lorenzo Oliveira; Maria Carmo P Nunes; Enrico Antonio Colosimo; Emilly Malveira de Lima; Clareci S Cardoso; Ariela Mota Ferreira; Lea Campos de Oliveira; Carlos Henrique Valente Moreira; Ana Luiza Bierrenbach; Desireé Sant Ana Haikal; Sérgio Viana Peixoto; Maria Fernanda Lima-Costa; Ester Cerdeira Sabino; Antonio Luiz P Ribeiro Journal: J Am Heart Assoc Date: 2020-03-11 Impact factor: 5.501
Authors: Ezequiel José Zaidel; Colin J Forsyth; Gabriel Novick; Rachel Marcus; Antonio Luiz P Ribeiro; Maria-Jesus Pinazo; Carlos A Morillo; Luis Eduardo Echeverría; Maria Aparecida Shikanai-Yasuda; Pierre Buekens; Pablo Perel; Sheba K Meymandi; Kate Ralston; Fausto Pinto; Sergio Sosa-Estani Journal: Glob Heart Date: 2020-10-13